Terms: = Prostate cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
855 results:
1. Chlordiazepoxide against signalling, receptor and regulatory proteins of breast cancer: a structure-based in-silico approach.
Alsaiari AA; Gharib AF; Bakhuraysah MM; Alrehaili AA; Algethami SM; Alsaif HA; Al Harthi N; Hakami MA
Med Oncol; 2024 Apr; 41(5):117. PubMed ID: 38630325
[TBL] [Abstract] [Full Text] [Related]
2. The prevalence and clinical significance of her2 expression in prostate adenocarcinoma.
Estephan F; Lap CJ; Banagan J; Antonio M; Liu S; Diao G; Rozalen AZ; Rajendran R; Krasnow S; Subrahmanyam R; Nava VE; Jain M
Ann Diagn Pathol; 2023 Dec; 67():152219. PubMed ID: 38622987
[TBL] [Abstract] [Full Text] [Related]
3. The Predictive Role of Serum Lipid Levels, p53 and ki-67, According to Molecular Subtypes in Breast cancer: A Randomized Clinical Study.
Faur IF; Dobrescu A; Clim IA; Pasca P; Prodan-Barbulescu C; Tarta C; Neamtu AA; Brebu D; Neamtu C; Rosu M; Duta C; Clim A; Lazar G; Totolici B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612725
[TBL] [Abstract] [Full Text] [Related]
4. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
5. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
6. Oncocytoid Salivary Tumors: Differential Diagnosis and Utility of Newly Described Immunohistochemistry.
Katabi N
Head Neck Pathol; 2024 Mar; 18(1):20. PubMed ID: 38502259
[TBL] [Abstract] [Full Text] [Related]
7. Capivasertib: First Approval.
Shirley M
Drugs; 2024 Mar; 84(3):337-346. PubMed ID: 38388873
[TBL] [Abstract] [Full Text] [Related]
8. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; Mott F; Fan Y; Fan J; Peng P; Wang H; Ni S; Sun C; Qiang X; Levin WJ; Ngo B; Ru QC; Wu F; Javle MM
Oncologist; 2024 Apr; 29(4):e514-e525. PubMed ID: 38297981
[TBL] [Abstract] [Full Text] [Related]
9. Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift.
Tantawy MN; McIntyre JO; Yull F; Calcutt MW; Koktysh DS; Wilson AJ; Zu Z; Nyman J; Rhoades J; Peterson TE; Colvin D; McCawley LJ; Rook JM; Fingleton B; Crispens MA; Alvarez RD; Gore JC
Cancer Med; 2024 Feb; 13(3):e6812. PubMed ID: 38239047
[TBL] [Abstract] [Full Text] [Related]
10. Metastatic Lymph Node 64 (MLN64) Expression in Gastric cancer: The Clinical and Molecular Implications in Drug Resistance.
Li AX; Zeng JJ; Khan E; Dou QP; Zhuang X; Ji EK; Ruge F; Martin TA; Jia S; Jiang WG
Cancer Genomics Proteomics; 2024; 21(1):30-40. PubMed ID: 38151289
[TBL] [Abstract] [Full Text] [Related]
11. In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors.
Ni S; Li L; Sun X; Wang Y; Yu Q; Wang W; Gu Z; Yu Z; Wu D; Wu F; Jiang S; Peng P
Eur J Pharm Sci; 2024 Jan; 192():106658. PubMed ID: 38048851
[TBL] [Abstract] [Full Text] [Related]
12. Use of Drugs in Clinical Practice and the Associated Cost of cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study.
Carreras MJ; Tomás-Guillén E; Farriols A; Renedo-Miró B; Valdivia C; Vidal J; Saura C; Carles J; Felip E; Gorgas MQ; Tabernero J; Monterde J
Curr Oncol; 2023 Aug; 30(9):7984-8004. PubMed ID: 37754495
[TBL] [Abstract] [Full Text] [Related]
13. An Overview of Recent Findings that Shed Light on the Connection between Fat and cancer.
Pandit P; Shirke C; Bhatia N; Godad A; Belemkar S; Patel J; Zine S
Endocr Metab Immune Disord Drug Targets; 2024; 24(2):178-193. PubMed ID: 37489790
[TBL] [Abstract] [Full Text] [Related]
14. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
Coombes RC; Howell S; Lord SR; Kenny L; Mansi J; Mitri Z; Palmieri C; Chap LI; Richards P; Gradishar W; Sardesai S; Melear J; O'Shaughnessy J; Ward P; Chalasani P; Arkenau T; Baird RD; Jeselsohn R; Ali S; Clack G; Bahl A; McIntosh S; Krebs MG
Nat Commun; 2023 Jul; 14(1):4444. PubMed ID: 37488191
[TBL] [Abstract] [Full Text] [Related]
15. The role of area-level socioeconomic disadvantage in racial disparities in cancer incidence in metropolitan Detroit.
Purrington KS; Hastert TA; Madhav KC; Nair M; Snider N; Ruterbusch JJ; Schwartz AG; Stoffel EM; Peters ES; Rozek LS
Cancer Med; 2023 Jul; 12(13):14623-14635. PubMed ID: 37184135
[TBL] [Abstract] [Full Text] [Related]
16. Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive cancers: Breast cancer, Cervical cancer, Endometrial cancer, Ovarian cancer and prostate cancer.
Korbecki J; Bosiacki M; Barczak K; Łagocka R; Brodowska A; Chlubek D; Baranowska-Bosiacka I
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108425
[TBL] [Abstract] [Full Text] [Related]
17. Electrochemical aptasensor based on the engineered core-shell MOF nanostructures for the detection of tumor antigens.
Khan S; Cho WC; Sepahvand A; Haji Hosseinali S; Hussain A; Nejadi Babadaei MM; Sharifi M; Falahati M; Jaragh-Alhadad LA; Ten Hagen TLM; Li X
J Nanobiotechnology; 2023 Apr; 21(1):136. PubMed ID: 37101280
[TBL] [Abstract] [Full Text] [Related]
18. Development of new TAK-285 derivatives as potent EGFR/her2 inhibitors possessing antiproliferative effects against 22RV1 and PC3 prostate carcinoma cell lines.
Son S; Elkamhawy A; Gul AR; Al-Karmalawy AA; Alnajjar R; Abdeen A; Ibrahim SF; Alshammari SO; Alshammari QA; Choi WJ; Park TJ; Lee K
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2202358. PubMed ID: 37096560
[TBL] [Abstract] [Full Text] [Related]
19. Association of high-grade prostatic intraepithelial neoplasia immunohistochemical profile with acinar adenocarcinoma of the prostate.
Dantés-Durán MA; Castelán-Maldonado EE; Palacios-Saucedo GDC
Gac Med Mex; 2023; 159(2):91-95. PubMed ID: 37094236
[TBL] [Abstract] [Full Text] [Related]
20. Frequencies of an Immunogenic her-2/
Goulielmaki M; Stokidis S; Anagnostou T; Voutsas IF; Gritzapis AD; Baxevanis CN; Fortis SP
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983028
[TBL] [Abstract] [Full Text] [Related]
[Next]